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Stromal Cells for Potential
Fetal Treatment of Hemophilia A
Priyadarsini Kumar1, Kewa Gao1,2, Chuwang Wang1,2,
Christopher Pivetti1, Lee Lankford1, Diana Farmer1,
and Aijun Wang1
Abstract
Hemophilia A (HA) is an X-linked recessive disorder caused by mutations in the factor VIII (FVIII) gene leading to deficient
blood coagulation. The current standard of care is frequent infusions of plasma-derived FVIII or recombinant B-domain-
deleted FVIII (BDD-FVIII). While this treatment is effective, many patients eventually develop FVIII inhibitors that limit the
effectiveness of the infused FVIII. As a monogenic disorder, HA is an ideal target for gene or cell-based therapy. Several studies
have investigated allogeneic stem cell therapy targeting in utero or postnatal treatment of HA but have not been successful in
completely correcting HA. Autologous in utero transplantation of mesenchymal stem cells is promising for treatment of HA
due to the naive immune status of the fetal environment as well as its potential to prevent transplant rejection and long-term
FVIII inhibitor formation. HA can be diagnosed by chorionic villus sampling performed during the first trimester (10 to 13 wk)
of gestation. In this study, we used an established protocol and isolated placenta-derived mesenchymal stromal cells (PMSCs)
from first trimester chorionic villus tissue and transduced them with lentiviral vector encoding the BDD-FVIII gene. We show
that gene-modified PMSCs maintain their immunophenotype and multipotency, express, and secrete high levels of active FVIII.
PMSCs were then transplanted at embryonic day 14.5 (E14.5) into wild-type fetuses from time-mated pregnant mice. Four
days after birth, pups were checked for engraftment, and varying levels of expression of human green fluorescent protein were
found in the organs tested. This study shows feasibility of the approach to obtain PMSCs from first trimester chorionic villus
tissue, genetically modify them with the FVIII gene, and transplant them in utero for cell-mediated gene therapy of HA. Future
studies will involve evaluation of long-term engraftment, phenotypic correction in HA mice, and prevention of FVIII inhibitor
development by this approach.
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Introduction
Hemophilia A (HA) is an X-linked recessive bleeding disor-
der caused by mutations in the gene encoding factor VIII
(FVIII), a protein essential for blood clotting. HA occurs in
*1 in 5,000 male births1. Patients with severe HA, defined as
FVIII activity less than 1%, suffer from debilitating hemar-
throses (bleeds in the joints), life-threatening internal bleed-
ing, and potentially fatal intracranial hemorrhages2. The
current standard of care for HA is FVIII protein substitution
therapy (PST), which offers reliable prophylactic and thera-
peutic relief from bleeding episodes and decreases the
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incidence of childhood hemophilic arthropathy3. However,
PST is not a cure, is prohibitively expensive, and is unavail-
able to*75% of the world’s HA patients. In addition,*30%
of HA patients undergoing PST develop inhibitory antibodies
to FVIII, increasing morbidity and mortality and drastically
increasing the cost of treatment4–6. Novel therapies to achieve
sustained FVIII expression in HA patients are needed to over-
come the serious limitations of current treatments.
As a monogenic disorder with a broad therapeutic
window, HA is considered a highly attractive target for gene
therapy7, and even a small increase in FVIII levels substan-
tially decreases complications. A recent landmark clinical
trial in hemophilia B (in which clotting factor IX [FIX] is
deficient) showed that gene therapy achieved FIX expression
in two-thirds of the patients8. However, such success has not
been achieved for HA because of the distinct molecular
complexity of FVIII9,10. Moreover, issues surrounding the
durability of gene expression by gene therapy and host
immune responses against gene transfer vectors remain11.
Cell-based gene therapy has been actively investigated to
treat HA because if engrafted successfully, the transplanted
cells could provide sustained production of FVIII and may
represent a curative treatment. So far, mesenchymal stromal
cells (MSCs), endothelial cells, endothelial progenitor cells
(EPCs), and other types of cells have been investigated for
HA treatment, some of which have shown promising pheno-
typic correction in animal models12–23. Postnatal expression
of FVIII could provoke an immune response that precludes
long-term and sustained FVIII expression24. In contrast to
the postnatal environment, the fetal environment contains
numerous characteristics that may allow improvement in
stem cell–based therapies. The fetal environment is benefi-
cial to stem cell engraftment because it is naturally receptive
to remodeling and regeneration of fetal tissues by stem
cells and it is highly conducive to expansion of stem cell
compartments12,25–28. Indeed, large-scale migration of stem
cells occurs naturally only in fetal life, allowing the systemic
distribution of the transplanted stem cells. If stem cells are
transplanted in utero, the unique regenerative gestational
environment may promote engraftment into developing
tissues, supporting long-term survival and functionality
of the transplanted cells29. The immunological naı¨vete´ of
the early gestation fetus is thought to be predisposed to
achieving tolerance to foreign antigens if presented before a
critical window30 and may enable tolerance induction, pre-
venting later inhibitory FVIII-antibody formation31. Addition-
ally, the fetus is much smaller in size allowing the delivery of
proportionately more cells than can be given postnatally27.
Chorionic villus sampling (CVS) performed during 10 to
13 wk of gestation allows genetic disorders such as HA to be
diagnosed early in pregnancy. Cells obtained from this tissue
could be a potential source of autologous therapy for HA by in
utero transplantation (IUT) of FVIII gene-modified cells prior
to the development of the immune regulatory system in the
fetus. We have previously established a tissue explant culture
protocol to isolate placenta-derived MSCs (PMSCs) from the
chorionic villus of placenta tissue that possesses all the
properties of MSCs32. Full-length FVIII is very complex and
challenging to use for the purpose of cell transduction.
B-domain-deleted FVIII (BDD-FVIII) is a shorter form of
FVIII where the heavily glycosylated B domain is deleted and
has been shown to be as functionally active as the full-length
FVIII33. In this study, we test the feasibility of isolating
PMSCs from first trimester chorionic villus tissue and suc-
cessfully transducing them with the BDD-FVIII gene to
express functional FVIII. We then evaluated the potential of
the BDD-FVIII expressing PMSCs for IUT in wild-type mice.
Materials and Methods
Isolation and Expansion of PMSCs from Human
Early Gestation Placenta
Discarded deidentified first trimester gestation placental tis-
sue (11 to 12 wk) was collected at the University of Califor-
nia, Davis (UCD) Medical Center. The study was submitted
to the UCD Institutional Review Board (IRB) and deter-
mined to be exempt from review.
PMSCs were isolated from dissected chorionic villus tissue
by using our well-established explant culture method developed
in our laboratory32,34. Isolated cells were cultured in complete
culture media for PMSCs consisting of high-glucose Dulbecco’s
modified Eagle’s medium (DMEM) with 10% fetal bovine
serum (FBS; Hyclone, Thermo Fisher Scientific, Logan, UT,
USA) and 100 U/mL penicillin and 100 mg/mL streptomycin.
Passages 4 to 7 were used in all our studies presented here.
Lentiviral Vector Transduction of PMSCs
All lentiviral constructs were synthesized at the UCD Insti-
tute for Regenerative Cures (IRC) vector core. For creating
BDD-FVIII-expressing lentiviral vector, plasmid containing
BDD-FVIII complementary DNA (cDNA) was purchased
from Addgene (plasmid #46775), and cDNA was inserted
into the lentiviral vector pCCLc (Takara Bio USA Inc,
Mountain View, CA, USA) that confers neomycin resis-
tance: pCCLc-MNDU3-BDD-FVIII-PGK-NEO-WPRE.
The control vector did not have the BDD-FVIII sequence:
pCCLc-MNDU3-PGK-NEO-WPRE. Luciferase (LUC) and
enhanced green fluorescent protein (EGFP) containing len-
tiviral vector (pCCLc-MNDU3-LUC-PGK-EGFP-WPRE)
was created for tracking analysis. For transduction of lenti-
viral vectors, 1  106 cells were seeded in T150 flasks and
allowed to adhere overnight. Cells were double transduced
with either the BDD-FVIII vector or the control vector and the
LUC/GFP vector in transduction media consisting of high-
glucose DMEM, 10% FBS, and 8 mg/mL protamine sulfate
(MP Biomedicals, LLC, USA). All vectors were transduced at
a multiplicity of infection of 10 for 6 h. Cells were then
washed twice with 1 phosphate-buffered saline (PBS) and
cultured in complete media for 72 h. After 72 h, media con-
taining 200 mg/mL of G418 (EMD, Billerica, MA, USA) was
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added to the cells and screened for neomycin resistance for
7 d. This screening will eliminate cells that were transduced
with LUC/GFP vector only and retain the cells that had either
FVIII gene only or both FVIII and LUC/GFP genes. Cells
were then cultured and expanded in complete medium.
PMSC Characterization by Flow Cytometry and
Trilineage Differentiation
Cells were analyzed by flow cytometry as previously
described32,34. They were stained with FITC-CD44
(560977), PE-CD44 (51-9007656), PE-CD73 (561014),
APC-CD45 (560973), PE-CD31 (560983), APC-CD29
(561794), PE-CD90 (561970), PE-CD34 (550761), APC-
CD105 (562408), AF647-HLA-DR (563591), and
FITC-HLA-DR (555560), all from BD Biosciences, San
Jose, CA, USA and APC-HLA-G (BioLegend #335909) or
appropriate isotype controls (BioLegend #400221, B.D. #51-
9007655, 556650, 550854, and 556655). BD™ anti-mouse
Ig, k CompBeads were used to generate compensation con-
trols. Transduction efficiency was assessed by GFP flow
cytometry analysis. Flow cytometry was performed using
FACSCanto cytometer (BD Biosciences) for cell immuno-
phenotyping and an Attune NxT cytometer (Thermo Fisher
Scientific, Waltham, MA, USA) for GFP analysis. All data
were further analyzed using FlowJo software (version 10)
(FlowJo LLC, Ashland, OR, USA). Trilineage differentia-
tion of PMSCs to osteogenic, adipogenic, and chondrogenic
lineages before and after transduction was performed as
described earlier32,34.
Western Blot Analysis
Total lysates were obtained by incubating cells in radioim-
munoprecipitation assay buffer (RIPA) lysis buffer (Thermo
Fisher Scientific) supplemented with 1% Protease Inhibitor
Cocktail (Sigma-Aldrich, St. Louis, MO, USA) for 1 h at
4 C. The lysates were loaded onto 4% to 12% Bis-Tris SDS-
NuPAGE gels (Thermo Fisher Scientific), and the proteins
were transferred to nitrocellulose membrane (BioRad, Her-
cules, CA, USA). The membrane was blocked for 1 h in 1%
casein. The blocked membrane was incubated overnight
with 1:5,000 dilution of primary antibody (Hematologic
Technologies, Essex Junction, VT, USA) in 1% casein, then
washed with Tris-buffered saline with 0.5% Tween20 and
incubated with secondary antibody conjugated with horse-
radish peroxidase (Thermo Fisher Scientific). After further
washing, the membrane was incubated with chemilumines-
cent substrate (WestDura; Thermo Fisher Scientific) and
exposed to a ChemiDoc MP Imaging system (Bio-Rad).
Reverse Transcription Polymerase Chain Reaction
(RT-PCR)
Total RNA was obtained from cells using the RNeasyPlus
Mini kit (Qiagen, Germantown, MD, USA), and cDNA
synthesized from 1 mg of RNA using Superscript II Reverse
transcriptase (Thermo Fisher Scientific) was used in a poly-
merase chain reaction (PCR) using the following primers
FVIII: forward-50 cagtcttgaaacgccatcaa 30, reverse-50 aatccca-
gagcctctccact 30; glyceraldehyde 3-phosphate dehydrogenase
(GAPDH): forward-50 gccagcatcgccccacttga 30; reverse-50
cggtcgtagcggggtgaact 30. Genes were amplified using Accu-
Power PCR premix (Bioneer, Alameda, CA, USA) at an
annealing temperature of 60 C for 35 cycles and products
were analyzed using a 2% agarose gel.
Quantitative Polymerase Chain Reaction (qPCR)
Tissues were homogenized using a motorized tissue grinder
(Thermo Fisher Scientific). Total RNA was obtained using the
RNeasyPlus Mini kit (Qiagen) and cDNA was synthesized
from 1 mg of RNA using Superscript II Reverse transcriptase
(Thermo Fisher Scientific). For quantitative analysis, RT-PCR
was performed on a MX3005P thermocycler (Stratagene, La
Jolla, CA, USA) using SYBR green PCR master mix (Applied
Biosystems, Foster City, CA, USA). The primers used were
GAPDH: forward-50 attcaacggcacagtcaagg 30, reverse-50
tggatgcagggatgatgttc 30; EGFP primer: forward-50 agtccgccct-
gagcaaaga 30, reverse-50 tccagcaggaccatgtgatc 30. Genes were
amplified for 40 cycles with an annealing temperature of 58 C.
delta threshold cycle (DCt) values of GFP expression were
calculated using GAPDH as control.
Enzyme-Linked Immunosorbent Assay (ELISA)
Cells were seeded (5  105 cells/well of a 6-well culture
dish) and cultured in 2 mL of complete media. After 72 h,
conditioned media was collected and centrifuged at 1,877 
g for 10 min to remove cell debris and the cleared media was
stored at 80 C. FVIII protein present in undiluted condi-
tioned media was quantified using FVIII ELISA kit (Affinity
Biologicals, Ancaster, ON, Canada) per the manufacturer’s
instructions. Calibrator Plasma (Affinity Biologicals) was
used as the standard.
Chromogenic Assay
FVIII activity in undiluted conditioned media prepared as
described above was assessed using a Coamatic FVIII kit
(Chromogenix, West Chester, OH, USA) per the manufac-
turer’s instructions. Coagulation reference calibration
plasma (Technoclone, Wien, Austria) was used as the
standard.
Animals and Surgery
All animal procedures were approved by the UCD Institu-
tional Animal Care and Use Committee. All facilities used
during the study period were accredited by the Association
for the Assessment and Accreditation of Laboratory Animal
Care International. Time-mated C57BL/6 “wild-type” mice
were bred in-house at UCD. At E14.5, the mouse was placed
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under isoflurane anesthesia (5% induction, 2%maintenance)
and was positioned supine on a heat pad and maintained at
37 C, monitored by a rectal temperature probe. The abdo-
men was clipped of fur and prepped for surgery with alter-
nating rounds of 70% alcohol and beta iodine. A 2-cm
laparotomy was performed and the uterus was carefully
exteriorized with cotton applicators. The uterus was exam-
ined for the presence of fetuses and the number of normal
and nonviable fetuses was noted. One of the viable fetuses
was gently restrained through the uterus at the cranial and
caudal ends in order to immobilize the fetus, so that the fetal
abdomen was exposed to the surgeon. Care was taken to
avoid manipulation of the placenta. A glass pipette that had
been pulled to a pore size of 70 mm was loaded with 5 mL of
2.5  105 PMSCs that were resuspended in PBS mixed with
blue food coloring at a 1:10 ratio. Adding the blue food
coloring did not affect the viability of the cells tested by
trypan blue exclusion. With the aid of a 10 operating
microscope, the glass pipette was inserted through the uterus
and into the fetal intraperitoneal (IP) cavity, and the cell
suspension was injected into the IP space. The blue food
coloring allowed for visual confirmation that the cell suspen-
sion was injected correctly into the IP space and not into the
adjacent organs (intestine and liver). Each subsequent viable
fetus was injected in the same manner with the same PMSC
dose. The uterus was then returned to its original location in
the abdomen and the maternal laparotomy was closed in 2
layers with absorbable 4-0 vicryl suture. The mouse then
received a subcutaneous injection of 1 mL PBS for fluid
resuscitation and a 0.05 mg/kg dose of buprenorphine for
pain regulation. The animal was allowed to recover from
anesthesia and was given subsequent doses of buprenorphine
every 12 h for the first 2 postoperative days.
The mouse was allowed to carry her pregnancy to term and
gave birth to her pups via standard vaginal delivery at E20.5.
At postnatal day 4, each pup received an IP injection of
10 mL/kg luciferin (Gold Biotechnology, Olivette, MO, USA)
with a 30-gauge needle. At 10 min postinjection, the pups
were euthanized by CO2 inhalation and the heart, lungs, liver,
kidneys, and spleen were dissected free from the pups. The
organs were then placed on a plastic petri dish and were
imaged within 30 min of collection by an in vivo imaging
system (Kodak, Rochester, NY, USA) for expression of LUC
and GFP. Following imaging, organs were stored in RNA
later (Qiagen) for PCR analysis. Mean intensities and area
of tissues were calculated using Carestream Molecular Ima-
ging software, version 5 (Woodbridge, CT, USA). Since heart
tissue did not express any GFP, mean GFP intensity of heart
tissue was considered as the background. The total GFP inten-
sity of each tissue was calculated using the equation:
Total GFP intensity ¼ ðmean GFP intensity of tissue
 mean GFP intensity of heartÞ
 area of tissue:
Statistics
Data were reported as mean + SD (for flow cytometry
analysis) and mean + standard error of mean (SEM) for
Figure 1. Characterization of first trimester PMSCs. Representative phase contrast image showing first trimester PMSCs spindle-shaped
morphology (A) and differentiation into osteogenic (B), adipogenic (C), and chondrogenic (D) lineages. Flow cytometric analysis of MSC
immunophenotype for expression of surface markers (E) and quantitative analysis (F) are shown. n¼ 4 cell lines. 10magnification, scale bar
¼ 100 mm. PMSC, placenta-derived mesenchymal stromal cell; MSC, mesenchymal stromal cell.
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ELISA and chromogenic assays, respectively. Statistical
analysis was performed by unpaired Student’s t test using
PRISM 7 (GraphPad Software Inc., San Diego, CA, USA),
and differences were considered significant if P < 0.05.
Results
Derivation of PMSCs and FVIII Transduction
PMSCs were isolated from first trimester chorionic villus
tissue using our previously established explant culture
method32,34. The isolated cells showed the typical
spindle-shaped morphology of MSCs and were capable of
differentiation into osteogenic, adipogenic, and chondro-
genic lineages (Fig. 1A to D). They also possessed the
mesenchymal surface immunophenotype and were positive
for surface markers CD105 (98.7% + 2.2%), CD73
(99.15% + 1.32%), CD44 (99.85% + 0.17%), CD29
(99.95%+ 0.1%), and CD90 (92.25%+ 15.3%) and neg-
ative for CD31 (0.65%+ 0.6%), CD34 (1.42%+ 1.07%),
CD45 (0.68% + 0.32%), HLA-DR (0.48% + 0.15%),
and HLA-G (0.67% + 0.16%; Fig. 1E and F). To derive
FVIII-expressing PMSCs, we constructed a lentiviral vec-
tor pCCLc-MNDU3-BDD-FVIII-PGK-NEO-WPRE that
encoded the BDD-FVIII. PMSCs were then transduced
with this vector and screened for neomycin resistance
to ensure that all cells expressed the FVIII protein. For
tracking analysis after IUT, we transduced the cells with
a lentiviral vector that expressed LUC and GFP with a
transduction efficiency of 61.5% + 21% (Fig. 2A to D).
FVIII/LUC-GFP double transduced cells maintained their
trilineage differentiation potential (Fig. 2E to G). They also
retained their mesenchymal immunophenotype and
expressed the positive surface markers CD105 (98.63%
+ 0.73%), CD73 (98.43% + 1.79%), CD44 (99.85% +
0.3%), CD29 (99.95% + 0.06%), and CD90 (90.63% +
Figure 2. Characterization of PMSCs transduced with lentiviral vectors. Representative images of phase contrast (A), GFP (B), and overlay
of phase contrast and GFP (C). GFP flow cytometry analysis of PMSCs transduced with GFP-LUC vector for in vivo cell tracking (D).
Trilineage differentiation of transduced PMSCs into osteogenic (E), adipogenic (F), and chondrogenic lineages (G). Flow cytometric analysis
of MSC immunophenotype for expression of surface markers after transduction with both BDD-FVIII and GFP-LUC vectors (H) and
quantitative analysis (I) are shown. n ¼ 4 transduced PMSC cell lines. 10 magnification, scale bar ¼ 100 mm. PMSC, placenta-derived
mesenchymal stromal cell; MSC, mesenchymal stromal cell; GFP, green fluorescent protein; LUC, luciferase; BDD-FVIII, B-domain-deleted
factor VIII.
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18.5%) and were negative for CD31 (0.38% + 0.15%),
CD34 (0.91% + 0.68%), CD45 (0.72% + 0.5%),
HLA-DR (0.48% + 0.64%), and HLA-G (0.7% +
0.47%; Fig. 2H and I). Cells that were transduced with
lentiviral vector without the BDD-FVIII served as control
for all our in vitro analysis.
Analysis of BDD-FVIII Expression by PMSCs
The expression of BDD-FVIII by transduced PMSCs was
first analyzed by RT-PCR. FVIII was expressed only in
PMSCs transduced with the BDD-FVIII vectors (Fig. 3A,
lane 2). No expression was observed in PMSCs transduced
with the control vectors (Fig. 3A, lane 1). Western blot
analysis using a full-length FVIII antibody also showed
high expression of a 160 kDa band only in the BDD-FVIII
transduced cells (Fig. 3B, lane 2) and not in the control
cells (Fig. 3B, lane 1). The protein size corresponds to the
full-length BDD-FVIII that has not undergone posttransla-
tional processing.
To evaluate the secretion of BDD-FVIII by transduced
PMSCs, human FVIII enzyme-linked immunosorbent assay
(ELISA) was used to measure the secreted amount of FVIII
into the medium using human calibrator plasma as reference
standard. FVIII was secreted at significantly high levels
(3.67%+ 0.94%/106 cells) by BDD-FVIII transduced cells
compared to control cells (0.23% + 0.08%/106 cells; P ¼
0.0109; n¼ 4; Fig. 3C). To assess whether the secreted FVIII
protein was functionally active, a coagulation chromogenic
assay was used to test their activity using human plasma as
standard. FVIII activity was significantly higher in BDD-
FVIII transduced cells (1.11 + 0.11 International Units
(IU)/106 cells) compared to control cells (0.08 + 0.01 IU/
106 cells; P ¼ 0.0001; n ¼ 4; Fig. 3D).
IUT of Transduced PMSCs
BDD-FVIII-transduced MSCs (2.5  105 cells) were trans-
planted in utero intraperitoneally into wild-type mice at
14 d GA. Four days after birth, the organs (heart, lungs,
liver, spleen, and kidney) were dissected and subjected to
GFP (Fig. 4A, a to e, respectively) and LUC imaging anal-
ysis (Fig. 4A, f to j). Varied levels of expression were
observed in lungs, liver, spleen, and kidney. Heart tissue
that showed no expression (Fig. 4A, a) was used as our
background control for GFP quantitation (Fig. 4B). GFP
expression in the tissues was also correlated by quantitative
PCR analysis (Fig. 4C). Together the data confirmed that
PMSCs persisted 10 d after IUT in the immunocompetent
xenogeneic environment and engrafted in multiple organs
in the transplanted animals.
Discussion
HA caused by mutations in the FVIII gene that is involved
in blood coagulation serves as a good candidate for cell-
based therapy. One major advantage of cell-based therapy is
the sustained production of the protein by transduced cells
once they are engrafted. With respect to HA, even a sus-
tained 1% to 2% of clotting activity of FVIII protein will
alleviate many of the complications faced by HA
patients35–37. MSCs can be obtained from several tissue
sources and have numerous benefits for regenerative appli-
cations as a delivery vehicle. MSCs can be isolated and
expanded in large numbers in vitro and can be transduced
by FVIII-encoding lentiviral vectors. Due to the big size of
the FVIII gene, it was technically challenging to package all
3 genes (FVIII, GFP, and LUC) in the same vector and
achieve satisfactory transduction efficiency. Therefore, we
designed the dual-transduction approach used in this study
to facilitate both therapeutic function (FVIII production)
and tracking (GFP and LUC expression).
Figure 3. Assessment of FVIII expression by transduced PMSCs.
RT-PCR (A) and Western blot (B) analysis of expression of BDD-
FVIII by transduced PMSCs (A: lane 2 and B: lane 2, respectively),
compared to PMSCs transduced with control vector (A: lane 1 and
B: lane 1, respectively). Comparison of human FVIII secretion by
ELISA (C) and activity by chromogenic assay (D) between PMSCs
transduced with BDD-FVIII vector and PMSCs transduced with
control vector. n ¼ 4 pairs of PMSC cell lines. PMSC, placenta-
derived mesenchymal stromal cell; BDD-FVIII, B-domain-deleted
factor VIII; FVIII, factor VIII; RT-PCR, reverse transcription PCR;
ELISA, enzyme-linked immunosorbent assay.
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The neomycin screening eliminated all non-FVIII pro-
ducing cells, but the remaining FVIII-producing cells might
not be uniformly coexpressing the GFP/LUC vector. How-
ever, this did not limit our ability to detect the signal of GFP/
LUC after IUT as a sufficient percentage of the transplanted
cells expressed both vectors as shown in Fig. 4. MSCs may
play a role in immune modulation aiding in engraftment
after transplantation, but tumorigenicity of MSCs after trans-
duction with FVIII lentiviral vectors needs to be considered
for future long-term studies.
To circumvent the issue of immune rejection of trans-
planted cells, an autologous stem cell source is required25.
HA can be diagnosed in the first trimester of pregnancy by
CVS, and hence, the excess tissue obtained by this procedure
could serve as a source of autologous PMSCs29 for potential
therapeutic treatment. We have already established that
PMSCs can be derived from second trimester chorionic
villus tissue32,34. In this study, we show that PMSCs could
be obtained from first trimester chorionic villus that possesses
all the characteristics of MSC phenotype. We were then able
to transduce the PMSCs with a lentiviral vector that encodes
the BDD-FVIII gene and demonstrated that these transduced
PMSCs can express active FVIII protein. Full-length FVIII
and BDD-FVIII have been reported to undergo posttransla-
tional processing by furin cleavage into heavy and light
chain products38. In our case, we did not see any posttransla-
tional processing and instead we observed only the unprocessed
160 kDa protein. Nevertheless, based on our chromogenic
Figure 4. IUT of BDD-FVIII expressing PMSCs. Representative images of GFP (A, a to e) and luciferase (A, f to j) signaling in heart, lung, liver,
spleen, and kidney tissues, respectively, in pups 4 d after birth which was 10 d after IUT of BDD-FVIII-transduced PMSCs and quantitation of
GFP signaling as described in Methods (B). Quantitative real-time PCR analysis of EGFP expression in the tissues (C). n ¼ 4 pups. PMSC,
placenta-derived mesenchymal stromal cell; BDD-FVIII, B-domain-deleted factor VIII; FVIII, factor VIII; IUT, in utero transplantation; GFP,
green fluorescent protein.
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assay, the activity of the secreted protein was maintained. Inhi-
bition of furin has been shown to increase secretion and
decrease intracellular retention of BDD-FVIII in mammalian
cells and may be advantageous for HA therapy39.
One of the potential problems of any postnatal autologous
cell-based therapy of HA is the humoral response resulting in
the production of anti-FVIII antibodies leading to eventual
decreased efficiency of FVIII activity and eventual relapse
of the HA symptoms12. Hence, an in utero approach prior to
immune induction by the fetus to FVIII is required for this
therapy to be successful. In our study, we introduced the
FVIII transduced PMSCs in utero in wild-type mice at
E14.5 and have shown the persistence of these cells at least
for 10 d after transplantation in the immunocompetent xeno-
geneic environment. We have also tested IUT at other GAs;
however, the small size of the fetuses in mice makes IUT
earlier than E14 technically challenging. Compared to
humans where the first mature a/b T cells are seen at 10 to
12 wk of gestation, in mice it appears only in the final days of
fetal gestation40. Hence, in this mouse model, we are prob-
ably performing our cell transplantation prior to appearance
of T cells, which may allow for the observed immune toler-
ance of the introduced xenogeneic human PMSCs. We
observed varied levels of engraftment of PMSCs in the tis-
sues tested. Long-term engraftment of transplanted cells
plays a key role in the success of any cell-based therapy,
and for successful HA therapy, MSCs need to engraft in
organs close to the vasculature to secrete the synthesized
FVIII into circulation. To date several existing reports state
that MSCs show poor engraftment efficiency in spite of their
immunomodulatory characteristics, but those studies were
conducted in adults where the immune regulatory system
is completely different than the fetus41,42. Several studies
utilize MSCs for IUT in both animal models and human
patients with promising results27,43–47. Specifically for HA,
because of the nature of the disease low engraftment of
transplanted cells might be enough to alleviate many of the
symptoms of HA35–37. Future studies will involve long-term
engraftment of first trimester PMSCs and secretion of human
FVIII after IUT and subsequent tests in an HA mouse model
for phenotypic correction of HA and immune tolerance by
assessment of anti-FVIII antibodies. Long-term safety stud-
ies will also be performed to evaluate the tumorigenicity of
these FVIII-gene-modified transplanted cells. This study is a
stepping-stone for utilizing CVS-derived early gestational
PMSCs for cell-based therapy of HA.
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